Opaleye Management Inc., 10% Owner at Grace Therapeutics, Inc. (GRCE), bought 71,065 shares at $1.93 ($136K) on 2026-10-14, disclosed to the SEC on 2026-10-16.
Opaleye Management Inc., a 10% shareholder, executed a $21.7k purchase of 11,233 shares at $1.93, marking the largest insider trade in the company's history. This significant accumulation comes as the stock trades near its 52-week low, potentially signaling confidence in the biotech's recovery.
GRCE is down 10.1% over the last 5 days and 13.0% over the last 30 days, trading at $1.87, which is just 1.08% above its 52-week low of $1.85.
Insider cluster: This is the largest insider purchase ever recorded for the company, indicating a strong signal of conviction from major shareholders.
Short interest: The stock has a short interest of 9.45% of the float, which could lead to volatility if the buying momentum accelerates.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.93 | 11,233 | $22K | 16.0% |
| 2 | $1.95 | 23,485 | $46K | 33.5% |
| 3 | $1.89 | 36,347 | $69K | 50.5% |
| Total | $1.92 avg | 71,065 | $136K | 100% |
| Filing → |
| GRCE | BUY | 2026-10-01 | $16K | — | Filing → |
| GRCE | BUY | 2026-09-23 | $32K | — | Filing → |
| ACOG | BUY | 2026-09-16 | $1.1M | — | Filing → |